Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Intensive Care Medicine · Toxic Shock Syndrome

ICU Care: The Four Pillars of TSS Treatment

At a Glance

Treatment for Toxic Shock Syndrome (TSS) in the ICU relies on four critical pillars: specialized antibiotics like clindamycin to stop toxin production, source control to physically remove the infection, aggressive cardiovascular support, and sometimes IVIG therapy to neutralize toxins in the blood.

Treating Toxic Shock Syndrome (TSS) in the Intensive Care Unit (ICU) requires a fast-moving, multi-pronged approach. Because the body is being overwhelmed by a “cytokine storm” of toxins, doctors must do more than just kill the bacteria—they must stabilize the body’s systems while stopping the toxin “factory” at its source [1][2].

The standard of care is built on four critical pillars.

Pillar 1: Targeted Antibiotics (The Toxin “Off-Switch”)

While standard antibiotics like Vancomycin or beta-lactams are used to kill the bacteria themselves, TSS requires a special second antibiotic: Clindamycin [3][4].

  • Why Clindamycin? In a typical infection, bacteria are killed slowly. However, some antibiotics can actually cause bacteria to release more toxins as they die. Clindamycin works differently; it is a protein synthesis inhibitor [2]. It essentially “shuts off” the machinery inside the bacteria that creates the toxins, independent of how it kills the bacteria [5][6].
  • Immunomodulation: Clindamycin may also help dampen the body’s overactive inflammatory response [6].

Pillar 2: Source Control (Removing the “Factory”)

Antibiotics cannot always reach the “heart” of an infection if it is trapped inside a wound or a foreign object. Source control is the immediate physical removal of the site where toxins are being produced [7][8].

  • Foreign Bodies: This includes the urgent removal of tampons, nasal packing, or even medical implants like IUDs or breast implants if they are suspected sources [9][10].
  • Surgical Debridement: If the TSS is caused by a skin or soft-tissue infection (common in Strep TSS), a surgeon must often physically remove the infected or dead tissue (debridement) to stop the spread of the toxins [11][12].

Pillar 3: Hemodynamic Support (Stabilizing the Heart and Lungs)

The “vascular leak” caused by TSS toxins causes blood pressure to crash. The ICU team uses several tools to keep blood flowing to vital organs [13][14]:

  • Aggressive Fluids: Large amounts of intravenous (IV) fluids are given to fill the “leaky” blood vessels [15].
  • Vasopressors: Medications like norepinephrine that tighten blood vessels to force blood pressure back up [1].
  • Advanced Support (ECMO): In rare, extreme cases where the heart or lungs begin to fail completely, a machine called ECMO (Extracorporeal Membrane Oxygenation) may be used to circulate and oxygenate the blood outside the body [15][14].

Pillar 4: Adjunctive Therapies (IVIG)

Intravenous Immunoglobulin (IVIG) is a specialized treatment made from the antibodies of thousands of healthy donors [3].

  • How it works: The hope is that these donor antibodies will “neutralize” or “mop up” the toxins circulating in the patient’s blood [3][16].
  • The Debate: The use of IVIG is controversial. Some studies suggest it can lower mortality in severe Strep TSS, while others show no significant benefit [17][18]. Because of this, IVIG is not always “standard” for every patient; it is often reserved for those who are not responding to other treatments [19][20].

Treatment Completeness Checklist

If your loved one is in the ICU for TSS, you should see evidence of these four actions in their care plan:

  • [ ] Infectious Disease Consultation: Specialist doctors should be managing the complex antibiotic mix [21].
  • [ ] Dual Antibiotics: A combination including Clindamycin to stop toxin production [22].
  • [ ] Source Inspection: A physical search for the entry point (wounds, tampons, or recent surgery sites) [23].
  • [ ] Organ Monitoring: Continuous tracking of kidney function (creatinine) and blood clotting (platelets) [24][25].

Common questions in this guide

Why is clindamycin used to treat Toxic Shock Syndrome?
Clindamycin is uniquely important in TSS because it acts as a protein synthesis inhibitor. Instead of just killing the bacteria slowly, it immediately shuts down the bacteria's ability to manufacture and release the harmful toxins causing the severe reaction.
What does source control mean in TSS treatment?
Source control refers to the urgent physical removal of whatever is causing the infection and producing toxins. This can involve removing foreign objects like tampons, nasal packing, or medical implants, as well as surgically removing infected or dead tissue.
How do doctors fix low blood pressure during a TSS crisis?
TSS toxins cause a vascular leak that makes blood pressure drop dangerously low. ICU teams stabilize patients using large amounts of intravenous fluids and vasopressor medications to tighten blood vessels, occasionally using an ECMO machine for severe heart or lung failure.
What is IVIG and when is it used for Toxic Shock Syndrome?
Intravenous Immunoglobulin (IVIG) is a specialized therapy made from healthy donor antibodies that may help neutralize circulating toxins in the blood. It is often reserved for patients who have severe TSS and are not responding adequately to other standard treatments.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is clindamycin part of the antibiotic regimen to specifically stop toxin production?
  2. 2.Has a surgical consultation occurred to ensure all potential 'sources' of infection, like deep-seated tissue or foreign bodies, have been addressed?
  3. 3.If blood pressure remains low despite fluids and standard medications, what is the plan for advanced hemodynamic support (like vasopressors or ECMO)?
  4. 4.Are we at a point where adjunctive therapies like IVIG (Intravenous Immunoglobulin) should be considered to help neutralize the toxins?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (25)
  1. 1

    Streptococcal toxic shock syndrome in the intensive care unit.

    Schmitz M, Roux X, Huttner B, Pugin J

    Annals of intensive care 2018; (8(1)):88 doi:10.1186/s13613-018-0438-y.

    PMID: 30225523
  2. 2

    Adjunctive protein synthesis inhibitor antibiotics for toxin suppression in Staphylococcus aureus infections: a systematic appraisal.

    Campbell AJ, Dotel R, Blyth CC, et al.

    The Journal of antimicrobial chemotherapy 2019; (74(1)):1-5 doi:10.1093/jac/dky387.

    PMID: 30307507
  3. 3

    Polyspecific Intravenous Immunoglobulin in Clindamycin-treated Patients With Streptococcal Toxic Shock Syndrome: A Systematic Review and Meta-analysis.

    Parks T, Wilson C, Curtis N, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2018; (67(9)):1434-1436 doi:10.1093/cid/ciy401.

    PMID: 29788397
  4. 4

    Infections Caused by Group C and G Streptococcus (Streptococcus dysgalactiae subsp. equisimilis and Others): Epidemiological and Clinical Aspects.

    Baracco GJ

    Microbiology spectrum 2019; (7(2)) doi:10.1128/microbiolspec.GPP3-0016-2018.

    PMID: 30977463
  5. 5

    The eternal dilemma of antitoxin antibiotics for skin and soft tissue infection.

    Burillo A, Bouza E

    Current opinion in infectious diseases 2021; (34(2)):80-88 doi:10.1097/QCO.0000000000000711.

    PMID: 33560018
  6. 6

    A clindamycin acetylated derivative with reduced antibacterial activity inhibits articular hyperalgesia and edema by attenuating neutrophil recruitment, NF-κB activation and tumor necrosis factor-α production.

    Rodrigues FF, Lino CI, Oliveira VLS, et al.

    International immunopharmacology 2023; (122()):110609 doi:10.1016/j.intimp.2023.110609.

    PMID: 37429145
  7. 7

    Managing the deteriorating child with suspected group A Streptococcus infection.

    Kempsell-Smith M, Fitzsimons C

    Nursing children and young people 2023; (35(6)):35-42 doi:10.7748/ncyp.2023.e1467.

    PMID: 37599641
  8. 8

    IntegraⓇ dermal regeneration template as the nidus of staphylococcal toxic shock syndrome: A case report.

    Gonzalez SR, Yuen JC

    JPRAS open 2020; (25()):24-29 doi:10.1016/j.jpra.2020.05.003.

    PMID: 32613072
  9. 9

    Toxic Shock Syndrome Caused by Staphylococcal Infection After Breast Implant Surgery: A Case Report and Literature Review.

    Hisanaga K, Kadota H, Fukushima S, et al.

    Annals of plastic surgery 2019; (83(3)):359-362 doi:10.1097/SAP.0000000000001868.

    PMID: 31268945
  10. 10

    Streptococcal toxic shock syndrome in the setting of recent gynecologic surgery: A case report.

    Gruttadauria M, Pollard J, Kim S, Lian X

    Case reports in women's health 2021; (32()):e00352 doi:10.1016/j.crwh.2021.e00352.

    PMID: 34466390
  11. 11

    Streptococcal Toxic Shock Syndrome: Life Saving Role of Peritoneal Lavage and Drainage.

    Yokoyama M, Oyama F, Ito A, et al.

    Clinical medicine insights. Case reports 2016; (9()):75-7 doi:10.4137/CCRep.S40217.

    PMID: 27579001
  12. 12

    Another Fatality Due to Postpartum Group A Streptococcal Endometritis in the Modern Era.

    Singhal A, Alomari M, Gupta S, et al.

    Cureus 2019; (11(5)):e4618 doi:10.7759/cureus.4618.

    PMID: 31312545
  13. 13

    Similarities and Differences Between Staphylococcal and Streptococcal Toxic Shock Syndromes in Children: Results From a 30-Case Cohort.

    Javouhey E, Bolze PA, Jamen C, et al.

    Frontiers in pediatrics 2018; (6()):360 doi:10.3389/fped.2018.00360.

    PMID: 30547021
  14. 14

    Successful treatment of out-of-hospital cardiopulmonary arrest due to streptococcal toxic shock syndrome - effectiveness of extracorporeal membrane oxygenation and the rapid antigen group A streptococcus test: a case report.

    Mizuguchi Y, Taniguchi N, Takahashi A

    Journal of medical case reports 2018; (12(1)):244 doi:10.1186/s13256-018-1780-2.

    PMID: 30170621
  15. 15

    Sequential Extracorporeal Therapy of Pathogen Removal Followed by Cell-Directed Extracorporeal Therapy in Streptococcal Toxic Shock Syndrome Refractory to Venoarterial Extracorporeal Membrane Oxygenation: A Case Report.

    Amerson SJ, Hoffman M, Abouzahr F, et al.

    Critical care explorations 2024; (6(3)):e1058 doi:10.1097/CCE.0000000000001058.

    PMID: 38415021
  16. 16

    Early intravenous immunoglobulin therapy for group A β-haemolytic streptococcal meningitis with toxic shock syndrome.

    Adigbli D, Rozen V, Darbar A, Janin P

    BMJ case reports 2021; (14(3)) doi:10.1136/bcr-2020-238472.

    PMID: 33664027
  17. 17

    Acute abdomen: a rare presentation of group a streptococcal infection.

    Lubach J, Vannijvel M, Stragier H, et al.

    Acta chirurgica Belgica 2023; (123(4)):440-443 doi:10.1080/00015458.2022.2040108.

    PMID: 35775101
  18. 18

    Effectiveness of intravenous immunoglobulin therapy for invasive group A Streptococcus infection: A Japanese nationwide observational study.

    Senda A, Endo A, Fushimi K, Otomo Y

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2023; (135()):84-90 doi:10.1016/j.ijid.2023.08.011.

    PMID: 37586661
  19. 19

    Intravenous immunoglobulin for adjunctive treatment of severe infections in ICUs.

    Aubron C, Berteau F, Sparrow RL

    Current opinion in critical care 2019; (25(5)):417-422 doi:10.1097/MCC.0000000000000639.

    PMID: 31335381
  20. 20

    Role of intravenous immune globulin in streptococcal toxic shock syndrome and Clostridium difficile infection.

    Shah PJ, Vakil N, Kabakov A

    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2015; (72(12)):1013-9 doi:10.2146/ajhp140359.

    PMID: 26025992
  21. 21

    Efficacy and side-effect profile of tedizolid in the treatment of streptococcal toxic shock syndrome due to clindamycin-resistant Streptococcus pyogenes: A case report.

    Yokota K, Kawakami K

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2024; (30(8)):785-788 doi:10.1016/j.jiac.2024.01.002.

    PMID: 38185364
  22. 22

    Early Diagnosis of Streptococcal Toxic Shock Syndrome With Abdominal Computed Tomography: A Case Report.

    Kurokawa R, Kurokawa M, Onoda S, et al.

    Cureus 2025; (17(8)):e90348 doi:10.7759/cureus.90348.

    PMID: 40970022
  23. 23

    Toxic shock syndrome associated with menstrual cup use.

    El Soufi H, El Soufi Y, Al-Nuaimi S, Bagheri F

    IDCases 2021; (25()):e01171 doi:10.1016/j.idcr.2021.e01171.

    PMID: 34141582
  24. 24

    Acute kidney injury in pediatric toxic shock syndrome is associated with worse clinical course in the intensive care unit.

    Weissbach A, Kaplan E, Kadmon G, et al.

    European journal of pediatrics 2023; (182(9)):4253-4261 doi:10.1007/s00431-023-05109-7.

    PMID: 37458817
  25. 25

    Streptococcus pyogenes Activates Human Platelets via Streptolysin S-Mediated Calcium Ion Influx.

    Riegner A, Jahn K, Wesche J, et al.

    Journal of innate immunity 2025; (17(1)):198-210 doi:10.1159/000544951.

    PMID: 40031874

This page explains the intensive care treatment protocols for Toxic Shock Syndrome (TSS) for educational purposes. It does not replace professional medical advice; always rely on your ICU team and infectious disease specialists for critical care decisions.

Get notified when new evidence is published on Bacterial toxic-shock syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.